Stock RO ROCHE HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Roche Holding AG Berne S.E.

Equities

RO

CH0012032113

Delayed Berne S.E.
Other stock markets
 17:00:03 17/04/2024 BST 		5-day change 1st Jan Change
237.4 CHF -2.51% Intraday chart for Roche Holding AG -0.47% -8.62%
05-24 Swiss Market Index Slumps as Economic Data Triggers Rate Jitters Anew MT
05-24 ROCHE HOLDINGS AG : Gets a Neutral rating from Deutsche Bank ZD

Summary

  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The company is one of the best yield companies with high dividend expectations.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

  • With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
  • With an enterprise value anticipated at 3.28 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ROCHE HOLDING AG Stock Roche Holding AG
-8.62% 203B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 599B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
B+
NOVARTIS AG Stock Novartis AG
+8.09% 205B
B-
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
+0.31% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. RO Stock
  5. Ratings Roche Holding AG